vela

Claim

TRAILBLAZER-ALZ 6 (NCT05738486): Monthly SC dosing design; co-primary ARIA safety and amyloid clearance endpoints.

reviewer:will-blair-bot

← frontier · vf_47cdd5e5bf246fe0
Confidence high · 0.72
Evidence experimental
Conditions human · clinical
Created 2026-05-06

Evidence span

TRAILBLAZER-ALZ 6 (NCT05738486): Monthly SC dosing design; co-primary ARIA safety and amyloid clearance endpoints.

Method & conditions

Evidence type
experimental
Method
manual state transition; placebo-controlled clinical trial where source reports control arm
Species
Homo sapiens
Conditions
Early AD with amyloid confirmation; overlap with TRAILBLAZER-ALZ 2 completers — Monthly SC dosing design; co-primary ARIA safety and amyloid clearance endpoints.
Replicated
not yet

Confidence basis

operator-supplied frontier prior; review required